With a combination of data from genome-wide association studies and epidemiological surveys, researchers said they have created a genetic tool capable of predicting aggressive prostate cancer’s age of onset.
0 Comments
New studies have discovered that the American Indians who live in urban regions, as well as Alaskan natives have significantly lower rates of survival when afflicted with cancer of the breast or prostate. It was found to be the same even in areas where the accessibility of healthcare is high and the same for all people. The findings of this study analyze the occurrence and the rate of survival of Alaskan natives and American Indians, as well as the percentage of those who stay in remission. Previous studies have also linked these races and ethnicities to a higher occurrence of cancer.
• Indian Health Service (IHS) collected the data: The Indian Health Service is within the aegis of the Department of Health and Human Services that provides health services to these two sects of people. Their facilities are found solitarily near the lands used as reservations for these people. • Concurs with other studies with other races: Other studies have also proved that, even though in some races and ethnic groups, cancer mortality has reduced, in others, it has not declined, it has either remained the same or gotten worse, especially in the populations of Alaskan natives and American Indians. • The data was collected from 582 people: Among the patients who visited the IHS centers, the data needed was compiled and analyzed from 582 Alaskan natives and American Indians, all of whom had some stage of breast cancer or prostate cancer. The new study took note of the cases which happened in an urban situation, selecting data from the patients who visited Kaiser Permanente Northern California. This is a healthcare system, which ensnares just about 33 percent of the inhabitants of Central Valley as well as the Bay Area. However, there are quite a few differences between the rate of cancer manifesting and the mortality rates, depending on the region, which warrant further study. Prostate cancer is one of the most common types of cancer to affect men. The diseaseis among one of the leading causes of cancer-related deaths in men, with critical statistics pointing out about one man in 38 die due to prostate cancer. This type of cancer mainly affects older men; about 6 cases in 10 are diagnosed in men within the age 61 years or older. Prostate cancer is a critical disease, but when diagnosed and treated early, it is not fatal.
Early cancer detection often gives room for more treatment options and provides a patient with better survival chances. This is because once a patient starts treatmentearly, cancer cells can be quickly killed. A simple blood test called the prostate-specific antigen (PSA) is used to test for prostate cancer, a digital rectal exam (DRE) can also be used as a part of the screening. Future screenings depend on the results of a prostate-specific antigen test: • Men who take the screening test and have a PSA under 2.5 ng/mL should go for retestingevery two years. • Its advisable to undergo Screening annually for men with a PSA level of at least 2.5 ng/mL. • All men who are over 55 years of age should undergo testing because prostate cancer usually shows no signs and symptoms in its early ages. Prostate cancer in its early stages usually shows no symptoms, but if they do occur, they may include: • Strain when urinating • Delays and burning sensation while passing urine • Loss of bladder control • A weak stream of urine • Urinating more often than usual • Blood in urine • Pain and stiffness in the lower back It is essential to see your doctor as soon as possible to seek medical attention if you are experiencing the symptoms listed above. |
AuthorAs the founder and medical director of the Prostate Seed Institute Dr. Gregory A. Echt. His vision to provide the most modern treatment, non surgical treatments for prostate cancer in various locations throughout the Dallas-Fort Worth continues to succeed. Now date, he has made a therapy for prostate implantation seed at over 2,500 men, including urologists and oncologists. Archives
December 2019
Categories |